Vanqua Bio
PrivateLast Round
Series B
Extension
Jul 1, 2024
Total Funding Raised
$130M
Company Overview
Vanqua Bio operates in Healthcare & Life Sciences and is based in Chicago, Illinois. Its latest recorded funding round was a Series B Extension round in July 2024.
Vanqua Bio is a biopharmaceutical company that discovers and develops innovative medicines for neurodegenerative and inflammatory diseases through small-molecule activators of glucocerebrosidase and innate immune system targeting.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vanqua Bio Comparables
Compare Vanqua Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuron23 | 91% | |
| Casma Therapeutics | 81% | |
| QurAlis | 81% |
For institutional investors. Book with your work email.
Vanqua Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jul 1, 2024 | ||||
| Series B | Sep 14, 2021 | ||||
| Series A | Oct 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vanqua Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B |
| SymBiosis Capital Management | Series B Extension |
| Omega Funds | Series B Extension, Series B |
| Avoro Ventures | Series B |
| Pontifax Credit | Series B |
| Osage University Partners | Series B |
| OrbiMed | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
Will present at the AD/PDTM 2026 conference in Copenhagen.
- Jul 24, 2024
$45M raised with Omega Funds and SymBiosis Capital Management.
For institutional investors. Book with your work email.
Vanqua Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vanqua Bio's valuation, stock price, and market status.
Is Vanqua Bio a public or private company?
Vanqua Bio is a private company.
What is the current stock price of Vanqua Bio?
Vanqua Bio is a private company, so its shares have no public market price. Caplight tracks Vanqua Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vanqua Bio worth (valuation)?
Valuation information for Vanqua Bio is not publicly available.
Can I buy Vanqua Bio stock?
Vanqua Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vanqua Bio's last funding round?
Vanqua Bio's most recent funding round was Series B Extension on July 1, 2024.
Who are the main investors in Vanqua Bio?
Key investors in Vanqua Bio include Omega Funds, OrbiMed.
Will Vanqua Bio IPO soon?
No public IPO plans have been announced for Vanqua Bio.
How can I track Vanqua Bio secondary market activity?
Caplight tracks bids, offers, and trades in Vanqua Bio's shares on secondary markets.